Findings

What do systematic reviews say?

1 questions · 1 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 1 · 100%

Hospitalisation for RSV infection · children (0 to 24 months)

Palivizumab leads to lower hospitalisation due to RSV infection compared with placebo, no intervention or standard care (high certainty).

1 finding from 1 review

Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children 2021 · Cochrane Headline outcomes only
RR 0.44 [0.3, 0.64]
5 studies · 3343 participants
High